A 52-year-old man with hypertension and stable angina presents to the cardiology clinic. He has been on amlodipine 5 mg daily for 6 months with suboptimal BP control (148/92 mmHg). His heart rate is 78/min, and ECG shows normal sinus rhythm with no acute changes. Fasting glucose is 126 mg/dL. The cardiologist decides to add a beta blocker. Which agent would be the LEAST appropriate choice in this patient?

Explanation

## Clinical Context This patient has hypertension, stable angina, and impaired fasting glucose (IFG/prediabetes). The question asks which beta blocker is LEAST appropriate—i.e., which carries the greatest risk or contraindication in this metabolic profile. ## Beta Blocker Selectivity & Metabolic Effects | Agent | Selectivity | Intrinsic Activity | Vasodilatory Property | Metabolic Impact | |-------|-------------|--------------------|-----------------------|-----------| | **Atenolol** | β₁-selective | None | None | ↑↑ Glucose intolerance, ↑ triglycerides, ↓ HDL | | **Metoprolol** | β₁-selective | None | None | ↑ Glucose intolerance (moderate) | | **Carvedilol** | Non-selective + α-block | Mild | Yes (α-blockade) | ↓ Glucose intolerance, ↑ insulin sensitivity | | **Bisoprolol** | β₁-selective | None | None | ↑ Glucose intolerance (moderate) | ## Why Atenolol is Least Appropriate **Key Point:** Atenolol is a non-vasodilatory, β₁-selective agent with the MOST pronounced adverse metabolic effects among commonly used beta blockers. 1. **Glucose intolerance**: Atenolol impairs glucose tolerance and increases the risk of new-onset diabetes—particularly problematic in a patient with prediabetes (FG 126 mg/dL). 2. **Lipid profile**: Atenolol increases triglycerides and reduces HDL cholesterol, worsening cardiovascular risk. 3. **Mechanism**: Non-selective blockade of β₂ receptors on pancreatic beta cells impairs insulin secretion; lack of vasodilatory property (unlike carvedilol) means no offsetting metabolic benefit. **High-Yield:** Among β₁-selective agents, atenolol has the worst metabolic profile. Carvedilol (non-selective with α-blockade) and bisoprolol (highly selective) are metabolically more favorable. **Clinical Pearl:** In diabetic or prediabetic patients, carvedilol is preferred because its α-blocking property causes peripheral vasodilation and improves insulin sensitivity—offsetting the β-blockade-induced glucose intolerance. ## Why the Others Are More Appropriate - **Metoprolol**: β₁-selective with moderate metabolic effects; acceptable in prediabetes if monitored. - **Carvedilol**: Non-selective + α-blocker; improves insulin sensitivity and is cardioprotective in heart failure; ideal for metabolic syndrome. - **Bisoprolol**: Highly β₁-selective with minimal metabolic impact; safe in prediabetes. **Mnemonic:** **"ACB for Metabolic Health"** — **A**tenolol (Avoid in prediabetes), **C**arvedilol (Choose for metabolic syndrome), **B**isoprolol (Best selective option).